<DOC>
	<DOCNO>NCT02150733</DOCNO>
	<brief_summary>This multi-center , open-label , Phase 1 study evaluate impact hepatic impairment pharmacokinetics Tivantinib cancer subject vary degree hepatic function , normal severely impaired .</brief_summary>
	<brief_title>Pharmacokinetics Tivantinib Subjects With Advanced Solid Tumors Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>1 . Subjects must histologically cytologically confirm advanced solid tumor . However , Hepatocellular Carcinoma ( HCC ) subject allow without histological confirmation long radiological diagnosis per standard criterion 2 . Male female ≥18 year age 3 . Life expectancy &gt; 12 week 4 . Women childbearing potential ( WOCBP ) must negative pregnancy test perform prior start study drug 5 . Male subject WOCBP must agree use double barrier contraceptive measure avoid intercourse study 90 day last dose study drug 6 . Subjects impaired hepatic function group accord ChildPugh classification score 7 . Subjects biliary obstruction biliary drain stent place eligible , provide drain stent place least 10 day prior first dose Tivantinib , subject 's liver function stabilize define 2 measurement least 5 day apart put subject hepatic impairment group 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≥2 9 . Adequate bone marrow renal function 10 . Ability provide write informed consent , comply protocol visit procedure , take oral medication , active infection chronic comorbidity would interfere therapy 11 . Fully informed illness investigational nature study protocol must sign date Institutional Review Boardapproved Informed Consent Form 1 . History liver transplant 2 . Any major surgical procedure within 3 week prior first dose study drug ; 3 . Active , clinically serious infection define ≥Grade 2 accord NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) , version 4.0 4 . Known metastatic brain meningeal tumor , unless subject &gt; 3 month definitive therapy clinically stable ( supportive therapy steroid anticonvulsant medication allow ) respect tumor time first dose study drug 5 . History cardiac disease Active coronary artery disease , define myocardial infarction , unstable angina , coronary bypass graft , stenting within 6 month prior study entry Evidence uncontrolled bradycardia cardiac arrhythmia define ≥Grade 2 accord NCI CTCAE , version 4.0 , uncontrolled hypertension 6 . Any condition unstable could jeopardize safety subject subject 's protocol compliance , include know infection human immunodeficiency virus 7 . Significant gastrointestinal disorder , opinion Investigator 8 . Pregnant breastfeed 9 . Received Tivantinib prior therapy 10 . Received anticancer therapy , include antibody , retinoid , hormonal treatment ( except megestrol acetate supportive care ) , radiation , within 3 week dose . Prior concurrent use hormone replacement therapy , use gonadotropinreleasing hormone modulators prostate cancer , use somatostatin analog neuroendocrine tumor permit 11 . Any investigational drug/medical device within 3 week prior first dose 12 . Substance abuse medical , psychological , social condition , opinion Investigator , may interfere subject 's participation clinical study evaluation clinical study result 13 . Subjects receive Coumadin anticoagulant 14 . Inability swallow oral medication 15 . Administration possibility initiate continue treatment know Cytochrome P450 3A4 ( CYP3A4 ) CYP2C19 enzyme Pglycoprotein alter drug ( inducer inhibitor ) non drug agent within 14 day prior dose primary objective phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>